Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMC-IMMUNIS CORP. -- Ignore unavailable to you. Want to Upgrade?

To: Ed Devlin who wrote (2)	1/15/2000 8:12:00 AM
From: Klaus Brandt	Read Replies (1) \| Respond to of 23

Hi Ed, Heard on an all news channel about this drug just two days ago. Where can I get more info ? Klaus

To: Ed Devlin who wrote (2)	1/15/2000 8:13:00 AM
From: Chuca Marsh	Read Replies (2) \| Respond to of 23

Klaus, Here you go-And Ed, read : Less Fat than Glue Farge:(( And the Side Effects is why I am here )) Glucophage Eat Broccoli or Take Muscle Cell Builder, rather than a Fat Cell Builder: healthyideas.com What Worries Me- The Big "O" < Olestra > < BTW- I WON't TOUCH it and I am a Big Rounded Guy!)Fat Question of this Century: healthyideas.com Fat Gender Discrimination, as is I worry that much: healthyideas.com Yet, I do: "...Women: Don't despair -- your naturally higher level of body fat protects you from the elements, allows you to bear and shelter children and even perform some physical activities more efficiently. ..." OUR PILL just may be THE WOMEN'S PILL of the 21st Century: Watch Thou Sugar, it makes you nuts ( and some need St Johns' )sometimes. Sometimes THE PILLs approved currently just WON'T FULLY AID and HELP the Whole Person- The Whole Problem, the Better Half of a Couple may need Fat Cell Control more than the other. < X'Cept for ME, LOL) Pills HELPING PEOPLE, Better-Smarter-Faster and LESS SIDE-EFFECT! Now The Sides: Each Person is an Individual:MORE CHOICES are NEEDED, IMHO: diabetesmonitor.com Pepto Bismol, you have to be kiding, Sides Effect will fade in time. inciid.org You see, I take St Johns' Wart in order to perform morte effectively ( except when I forget, LOL, since 1993; 3 - 4, big herb capsules are best <BTW rather than the studies that showed that mush solid pills are deviated in true amounts of the HERB> pills a day:There must be others like me out there, that is why I am here, in addition to earning income, I am assisting in what I believe in, so JOIN IN, FREEDOM OF CHOICE: inciid.org ragingbull.com ragingbull.com ragingbull.com All, we better remember that IMMC has 25% of Diabetes Type II and BIOHF does not own 25% of IMMC, IMMC has 25% of BIOHF. This fact is ONE HELL OF A BONUS when a decision in Buying into this NEWTECH is made here. REC- STRONG BYE. POSITION- LONG on any increase value, optioned from now on, just like any new investor. I get paid to write this, BUT I believe in the concept. Yet, Look at the price/volume that IMMC has done. 60 days chart at Bigcharts.com shows how we just got the New $2 Level while we had the "E" ON THE Symbol that just dropped of yesterday. bigcharts.com CHART on CSW shows the one month drop with the E on the Symbol Gap, and the recent recovery: chart.canada-stockwatch.com We have Eyes don't we. Now read my employers Website click on Immunis Corp: and see the chart at the Bottom, much better: stockmaster.com and News: news.stockmaster.com and the ASSETS are 13 Mill yet we have to break the Threashold past the minus 4 cents per share EPS, and with The Pipeline, IMHO, we will: news.stockmaster.com Nov 1999, Cash- 4 Million Dollars almost! Chucka-and they reported! SEC Disclosure on my Personal Profile a/c IMMC and CCI at www.brokerrelations.com P.S.- The Old Topten Links - I better search the Greatfull Med this weeks at the .gov website seacch to dig up some interesting URLs, Type II - stay turned. " techstocks.com techstocks.com siliconinvestor.com ? This link is so poped on today- 1 July that I haven't even read it, 2 Million Shares Volume today <7-1>...a desperate "HERE's THE URL" to the ARTICLE on DOW JONES REPORTER STORY on CYTO ...so I scraped the Thread URL...here..for now..Hit this one now - Edit Acess To Medical Journals-Gore announced FREE use! Database of medical information-National Library of Medicine. This new service is called "PubMed" and make avail over 9 million Med Jours-from 260+Academic/M. Jours.List by Name,Author/option to read ABSTRACT of NOT complete article.Bet Veep Surfs SI - Edit and American Gov'ntReseach Gratefull Med-Nat'l Library Is it a Ben & Jerry Ice(CherryGarcia) Cream? A Song or a Group? User ID code immediatly; dom or intl users. Cr.Cd or cash prepaid required.CS= mms@nim.nih.gov. There are 8 mill refs+Loansome Doc in Medline CS at www.nnlm.nlm.nih.gov $2.00 avg search - Edit An OTC Bulletin Board igm.nlm.nih.gov ChuckaII( Revised From Chucka2) LOL-Lots Of Laughter Due Dilly PR is Full: PRESS RELEASE ImmuNis Corp Symbol Change to IMMC FAIRFIELD, N.J., Jan 12, The President of ImmuNis Corp. (OTC Bulletin Board: IMMCE) and (OTC Symbol IMMC), Colin Leech-Porter, announced today that the company has been delayed in filing its first FORM 10. The company anticipates the filing to be completed prior to January 25, 2000. In keeping with the policy of the National Association of Securities Dealers, the Shares of ImmuNis Corp will be quoted in the OTC market only. The daily price for the shares may be obtained from Bloomberg Investor Services at their web site www.bloomberg.com/. At the home page enter the company's symbol "IMMC" to obtain the price and trading volume. Investors without access to the internet or a broker dealer to obtain the price of the shares are invited to call our shareholders relations service provider YES International at (800) 631-8127. ImmuNis purchased a 25% interest in the commercial rights to DIAB II in 1998 for territories outside of Oriental Asia. DIAB II was developed by Biotech Holdings Ltd., a Canadian-based pharmaceutical company, which controls the worldwide manufacturing and marketing rights to the drug. DIAB II is an insulin-receptor sensitizer, a new class of drugs for controlling the chronically high blood sugar levels that typify diabetes. DIAB II works by improving the patient's ability to utilize both endogenous and injected insulin, the hormone that controls blood sugar levels. Adult-Onset Diabetes is an illness affecting more than 15 million Americans and more than 150 million people around the world. The drug -- DIAB II -- provides excellent control of diabetes symptoms without the side-effects of many competing drugs. ImmuNis Corp. owns interests and invests in innovative health care modalities that address health problems afflicting populations in both developing countries and Western nations. The Company's interests may be in the form strategic partnerships, direct ownership interest in patents, participation in or control of commercial or marketing rights. Contact Rich Kaiser at YES International Investor Relations Services, (800) 631-8127. ---- End Included Message ----..Chuckastartofsomething. To HELP folks, ask your self why won't the FDA make it easy - it is LIFE THREATHENING in some ways - we ( USA folks ) deserve a FASTTRACK APPROVAL on such innovative PILLs, IMHO. The FIGHT STARTS HERE with OUR INFORMATIONAL LINKS! JOIN IN. First the WORLD- THEN THE Americas.

To: Ed Devlin who wrote (2)	1/15/2000 10:48:00 AM
From: Chuca Marsh	Respond to of 23

Here is another study of Comparison:IE- Why we are BETTER: as done by IMMC JV guys: Biotech Holdings Ltd - Biotech's DIAB II diabetes drug different from TZDs Biotech Holdings Ltd BIO Shares issued 37,252,913 1999-10-21 close $1 Friday Oct 22 1999 Mr. Robert Rieveley reports Robert B. Rieveley, president of Biotech Holdings, responding to investor and shareholder inquiries, has clarified some important differences between Biotech's DIAB II and TZDs such as SmithKline Beecham's Avandia, which yesterday received a negative opinion from the scientific advisory panel for the European Agency for the Evaluation of Medicinal Products. "While DIAB II is an insulin-sensitizing drug, DIAB II is not chemically related to the TZDs, or thiazolidinediones. DIAB II has a unique mechanism of action. At the same time, the data, most recently including a clinical trial in Brazil, strongly suggest that DIAB II is a very benign drug. DIAB II is very effective in reducing symptoms of type II diabetes but is also very safe." Mr. Rieveley added, "With the demonstrated lack of the toxicity that characterizes some insulin-sensitizing drugs and with demonstrated efficacy, we believe that DIAB II should become the market leader for insulin-sensitizing drugs wherever it is introduced." DIAB II works by improving the patient's ability to use both endogenous and injected insulin, the hormone that regulates blood sugar levels. Type II or adult-onset diabetes affects more than 15 million people in the United States, over 20 million in Latin America and over 150 million people worldwide. WARNING: The company relies upon litigation protection for "forward-looking" statements. canada-stockwatch.com brokerrelations.com From the BR.com website : Published by Deutsche Margan Grenfell Projections Immunis Corp. (IMMC-OTCBB) owns interests and invests in developing health care products that address health problems in both developing countries and industrialized nations. The company's interests may be in the form of strategic partnerships, direct ownership interests in patents or the control of commercial or marketing rights. The company's first acquisition was a 25% interest in the commercial rights to DIAB II (a type II diabetes treatment) territory outside of Oriental Asia. Product/Services 25% interest in commercial rights to DIAB II for territories outside of Oriental Asia. DIAB II is a potent member of a new class of anti-diabetic agents. Effective in treating Type II diabetes. 1) extremely safe: free of toxicity associated with glitazone-class insulin sensitizers 2) increases patient's metabolic rate: increasing energy and feeling of well-being 3) works mainly on muscle cells, not fat cells: weight reduction instead of weight gain 4) delivered by small easy-to-swallow coated tablets The Market The market for DIAB II in Latin America is a sizable and very lucrative market. To calculate the potential for revenues, for each one percent of the diabetic population in Brazil and Argentina using DIAB II (a total of 100,000 1-year prescriptions) DIAB II sales revenues generated would be over $20,000,000 per year. Over 150 million people suffer from diabetes worldwide. Worldwide market for Type II Diabetes treatment exceeds $10 billion annually U.S. market for insulin sensitizers expected to grow by more than 50% per year to $5.1 billion by end of 2003. Corporate Fundamentals/ News 1) Company has no debt 2) Profit margins as high as 60% 3) License agreement with Biobras of Brazil: 4th largest insulin producer in the world with over 75% of Brazilian market 4) Agreement for distribution in Argentina and Brazil in place, Peru, Ecuador, and Venezuela expected shortly 5) Research report including: DIAB II should have sales of close to $200 million U.S. by year-end 2003. Immunis Corp. would have 25% of profits based on those sales. Year Ending Revenue Pre-Tax Income 2000 (est.) $10 mm $6 mm 2001 (est.) $30 mm $18 mm 2002 (est.) $55 mm $33 mm 2003 (est.) $85 mm $51 mm CONTACT US For additional information contact John King at: Creative Consultations International 888-353-5210. email: jking@qnet.com or Mr. Roberts Hawke Group, Inc. 965-564-7114 This release contains forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, actual results may differ for reasons that include but are not limited to political and economic conditions in the countries in which the Company does or intends to do business, regulatory action, product pricing and competitive market conditions. DISCLAIMER: Information displayed by CREATIVE CONSULTATIONS INTERNATIONAL does not constitute on offer to buy or sell securities (stocks). CREATIVE CONSULTATIONS INTERNATIONAL does not recommend that any person(s) or institution(s) make buying or selling decisions due to any material on this site. All visitors to this web-site are strongly urged to consult a qualified financial professional before forming any opinions, making any decisions, or taking any actions in regards to information included on this web-site. CREATIVE CONSULTATIONS INTERNATIONAL accepts no responsibility for any investment decisions and we again strongly urge everyone to consult a financial professional before doing so. Safe Harbor Chucka - IMMC has 25% of DiabII. BIOHF doen not own 25% of IMMC, IMMC has 25% of BIOHF- SEC Disclosure applies to me as stated CCI, above.